Company intelligence / Profile preview

Kancera

Ownership: Public · KAN
Development stage: Phase 2

Overview

Kancera has advanced its lead candidate, KAND567, from preclinical to clinical development. Over 150 healthy subjects and patients have been treated with KAND567. The drug has completed three phase I studies and two phase IIa studies. Currently, it is being studied in the combined phase Ib/IIa KANDOVA study for ovarian cancer. The second-generation candidate, KAND145, offers improved product properties and shares the same mechanism of action as KAND567

Therapeutic areas: OncologyImmunology
Modalities: small molecules
Industry: Biotech

Drug pipeline

1 asset

KAN0441571C

Preclinical

Financials

Market cap: $1.3B
Total revenue: $775.9M
Enterprise value: $1.2B

Beyond the preview

Go deeper on Kancera.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kancera.

Explore the full profile